Steven A. Navarro concentrates on cross-border mergers and acquisitions (M&A), private equity transactions, joint ventures, and strategic alliances primarily in the life sciences, energy and natural resources, and industrial sectors. He advises private equity funds, and multinational public and private companies on complex acquisitions, dispositions, and securities transactions. His practice also encompasses public and private M&A, stock and asset transactions, and purchases and sales resulting from bankruptcy and out-of-court restructurings.
Steven also represents issuers in initial and subsequent public offerings; and issuers, as well as strategic and financial investors, in the private placement of the securities of publicly and privately held corporations. He is the New York office practice leader for corporate and business transactions, and a former co-leader of the firm’s mergers and acquisitions practice. He is also listed as a 2013-16 Legal Media Group Life Sciences Transactional “Life Sciences Star.”
Energy and Natural Resources
Represented BHP Billiton (ASX), an Australian natural resource company, in its $15.1 billion acquisition of Petrohawk Energy Corp. (NYSE), an owner of shale assets (the 8th largest deal of 2011 according to Corporate Control Alert).
Represented ABB Grain (ASX) on US securities matters relation to its $1.6 billion acquisition by Viterra (TSX).
Represented InterEnergy Partners LP, a private equity fund, in the acquisition and equity arrangements of a 120MW power plant in South America.
Represented InterEnergy Partners in the acquisition and equity arrangements of a non-control equity interest in a portfolio of power plants in South America of approximately 625MW and in the acquisition and equity arrangements in a non-control investment in a 300MW power plant in South America.
Represented a private equity fund in the acquisition and equity arrangements of a power distribution company in South America.
Represented private equity fund in investment in South American and Caribbean basin power generation business.
Represented Acerta Pharma in its $4 billion sale of a majority stake to AstraZeneca.
Represented Anterios to its in its $90 million sale to Allergan.
Represented OncoEthix in its $110 million sale to Merck with additional milestone payments of up to $265 million contingent upon certain clinical and regulatory events being achieved.
Represented New State Capital Partners in the acquisition of United Medical Systems.
Represented a Japanese pharmaceutical company in its acquisition of a development stage vaccine company for up to $250m.
Represented Marshall Edwards, Inc. (Nasdaq), an oncology focused company, in its acquisition of the isoflavone portfolio of Novogen Ltd. (ASX, Nasdaq) in exchange for convertible preferred stock.
Represented MEI Pharma in its acquisition of various compounds from S*Bio PTE LTD. for a combination of common stock and future cash payments.
Represented MEI Pharma in various PIPE and registered direct offerings.
Represented Chelsea Therapeutics in an "at-the-market" program.
Represented H Lundbeck A/S in the acquisition of Ovation Pharmaceuticals, a developer of CNS drugs (2009 Buyouts MagazineDeal of the Year).
Represented Chiesi Farmaceutici S.p.A. in its controlling investment in Cornerstone Therapeutics (Nasdaq), a maker of respiratory medicines.
Represented Chiesi in its 13e-3 take private of Cornerstone.
Represented Chelsea Therapeutics in its sale to Lundbeck for upfront cash of $6.44 per share plus a a CVR of up to $1.50 for total potential consideration of $658 million.
Represented Owens Corning in a $1.8 billion worldwide manufacturing joint venture and related equity transactions.
Represented Owens Corning in the $800m acquisition of a worldwide specialty glass yarns business.
Represented Ferro Corporation in the acquisition of a European and Asian ceramics business structured as an asset swap.
Represented Sun Capital, a private equity fund, in the sale of Sonneborn, Inc., a global specialty petro chemical manufacturer.
Represented Owens Corning in the joint venture of its cultured stone business.
Represented Sekesui in a US based manufacturing joint venture and related equity transaction.
Represented Sun Capital Partners in its $1.2 billion acquisition of ShopKo Stores, a publicly traded Midwestern based retailer and related equity investments by co-investors.
Represented ShopKo Stores in its $3 billion combination with Pamida Inc.
Represented financial participants in a $3 billion private equity acquisition of BJ's Wholesale Club.
Represented Sun Capital Partners in its acquisition of Friendly's Ice Cream (Nasdaq).
Georgetown University Law Center, 1987, J.D.
State University of New York at Albany, 1984, B.A.
Awards and Affiliations
Board of Trustees and Corporate Secretary, Hope Funds for Cancer Research
Notable Practitioner, IFLR1000 United States (2018)
Notable Practitioner, IFLR1000 Financial and Corporate (2019, 2020)
Recommended, M&A/corporate and commercial - M&A - large deals ($1bn+), The Legal 500 US (2017–2019)
Recommended, M&A/corporate and commercial - Venture capital and emerging companies, The Legal 500 US (2017)
Life Sciences Star, Financial and Corporate, LMG Life Sciences (2013–2019)